IEX •
Healthcare •
Biotechnology •
Quote as of 07/28/2026 15:59
Company Profile
IndustryBiotechnology
SectorHealthcare
ExchangeIEX
Market Capitalization10,159 mln
Float59.29 mln
Earnings Date08/17/2026
Piotroski F-Score
3
/ 9
Below average
1-Year Forecast
131
Fairly priced
Relative Strength
58
/ 100
Slightly ahead
Debt / Equity
0.01
Debt-free
ROE
-34.00
Deeply negative
Dividend Yield
0.00%
No dividend
Business Description
Apogee Therapeutics is a clinical-stage biotechnology company focused on developing new antibody-based medicines for inflammatory and immune-related conditions such as atopic dermatitis, asthma, eosinophilic esophagitis, and chronic obstructive pulmonary disease. Its pipeline includes several drug candidates at various stages of clinical testing, with its most advanced candidate, Zumilokibart, currently in Phase 2 trials for atopic dermatitis. Founded in 2022 and based in Waltham, Massachusetts, the company is working to bring improved treatment options to patients across the United States.
